Lilly Asia Ventures, an investor in the cancer drug developer since its series A round, returned to back a series C that doubled its overall funding to $140m.

China-based oncology therapy developer Abbisko Therapeutics closed a $70m series C round today that included Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly. Singaporean state-owned investment firm Temasek led the round, which also featured another Singaporean government investor, GIC, as well as Qiming Venture Partners, Jianxin Capital, CICC Capital and Loyal Valley…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.